Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Claritas Pharmaceuticals Inc

Healthcare US CLAZF

0.0001USD
0.00(0%)

Last update at 2026-06-23T20:00:00Z

Day Range

0.00010.0001
LowHigh

52 Week Range

0.00010.0001
LowHigh

Fundamentals

  • Previous Close 0.0001
  • Market Cap0.00436M
  • Volume250
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM0.90

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax - - -0.67400M -25.83400M 6.84M
Minority interest - - - - -
Net income - - 4.21M -21.21200M 6.93M
Selling general administrative - - 1.87M 3.66M 3.35M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - - -2.60810M -18.94800M -4.58800M
Ebitda - - -2.79210M -9.49700M -11.21700M
Depreciation and amortization 0.23M 0.24M -0.18400M 9.45M -6.62900M
Non operating income net other - - - - -
Operating income - - -3.27600M -25.87600M -4.58800M
Other operating expenses - - 0.18M 9.45M 11.10M
Interest expense - - 0.23M 0.21M 0.15M
Tax provision - - -4.88400M -4.62200M -0.09900M
Interest income - - - - -
Net interest income - - -0.27100M -0.25500M -0.26800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -4.88400M -4.62200M -0.09900M
Total revenue - - 0.00000M 0.00000M 0.00000M
Total operating expenses - - -0.18400M 9.45M 11.10M
Cost of revenue - - - - -
Total other income expense net - - -0.85800M -16.38300M 18.21M
Discontinued operations - - - - -
Net income from continuing ops - - 4.21M -21.21200M 6.93M
Net income applicable to common shares - - 4.21M -21.21200M 6.93M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets - - 10.45M 25.25M 59.61M
Intangible assets - - 7.69M 20.40M 49.40M
Earning assets - - - - -
Other current assets - - - - -
Total liab - - 8.94M 28.69M 49.85M
Total stockholder equity - - 1.51M -3.43700M 9.76M
Deferred long term liab - - - - -
Other current liab - - 4.22M 3.26M 4.59M
Common stock - - 56.51M - -
Capital stock - - 0.00000M 0.00000M 43.85M
Retained earnings - - -55.00700M -59.21700M -38.00500M
Other liab - - 1.81M 22.56M 42.03M
Good will - - 1.77M 4.69M 9.46M
Other assets - - 0.00600M 0.00800M -
Cash - - 0.00500M 0.03M 0.23M
Cash and equivalents - - - - -
Total current liabilities - - 7.13M 5.76M 7.82M
Current deferred revenue - - - - -
Net debt - - 0.92M 0.70M 0.02M
Short term debt - - - - -
Short long term debt - - 0.93M 0.36M 0.25M
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - - - - -
Total current assets - - 0.97M 0.15M 0.75M
Long term investments - - - - -
Net tangible assets - - -7.95700M -28.53100M -49.09900M
Short term investments - - - - -
Net receivables - - 0.21M 0.12M 0.52M
Long term debt - - - 0.37M 0.31M
Inventory - - - - -
Accounts payable - - 0.91M 1.56M 1.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.00600M 0.00800M -
Deferred long term asset charges - - - - -
Non current assets total - - 9.47M 25.10M 58.86M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Investments - - -0.18800M 0.00000M -
Change to liabilities - -5.36700M -4.26400M 0.96M -0.76900M
Total cashflows from investing activities - 0.00200M -0.18800M -0.18800M -10.00000M
Net borrowings - 0.07M 0.29M 0.29M 3.98M
Total cash from financing activities - 0.29M 6.48M 1.39M 18.57M
Change to operating activities - -0.27000M -0.73700M 0.62M 0.17M
Net income - 4.21M -21.21200M 6.93M -31.86300M
Change in cash - -0.04410M -0.19500M -3.45900M 3.01M
Begin period cash flow 0.00500M 0.03M 0.23M 3.69M 0.67M
End period cash flow 0.00500M -0.01210M 0.03M 0.23M 3.69M
Total cash from operating activities - -0.30900M -6.48300M -4.84800M -5.56100M
Issuance of capital stock - - 6.18M 3.23M -
Depreciation - 18.01M 33.33M - -
Other cashflows from investing activities - 0.00200M -0.00800M -0.00800M -0.00800M
Dividends paid - - - - -
Change to inventory - -0.10851M -0.53728M 0.54M 0.79M
Change to account receivables - -0.08949M 0.41M -0.38719M -0.09427M
Sale purchase of stock - - - - -
Other cashflows from financing activities - 0.29M -0.18800M -1.84400M -0.12717M
Change to netincome - 1.20M 19.33M -12.95300M 26.99M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - -5.56500M -4.39300M 1.12M -0.69000M
Stock based compensation - 0.00034M 0.00315M 0.88M 0.35M
Other non cash items - -12.04200M -15.12100M -13.77500M 26.65M
Free cash flow - -0.30900M -6.48300M -4.84800M -5.56100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CLAZF
Claritas Pharmaceuticals Inc		 - -% 0.0001 - - - - -0.3946
NVO
Novo Nordisk A/S		 0.03 0.05% 47.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.16 2.48% 48.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.92 1.28% 625.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.

Claritas Pharmaceuticals Inc

4040 Civic Center Drive, San Rafael, CA, United States, 94903

Key Executives

Name Title Year Born
Mr. Robert Farrell J.D. Chairman, CEO & Pres NA
Ms. Victoria Diana Rudman Interim CFO, Treasurer & Sec. 1968
Mr. Seth Yakatan Co-Founder 1970
Dr. Stuart L. Silverman Co-Chair of Scientific Advisory Board and VP of Medical Affairs 1947
Dr. Sari Prutchi-Sagiv Ph.D. Chief Scientific Officer NA
Dr. Moshe Yeshurun M.D. Chief Medical Officer NA
Dr. Amos Rosenthal Ph.D. Head of Chemistry NA
Mr. Robert Farrell J.D. Chairman, CEO & President NA
Ms. Victoria Diana Rudman Interim CFO, Treasurer & Secretary 1968
Dr. Stuart L. Silverman FACP, FACR, M.D. Chair of Scientific Advisory Board and Vice President of Medical Affairs 1947

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions